Topas Therapeutics Announces First Patient Enrolled in Phase 1 Trial with TPM203 in Pemphigus Vulgaris
First program from the Topas platform to enter clinical testing PM203 is one of several proprietary programs being developed by Topas Pemphigus vulgaris is an
Edinburgh Molecular Imaging Closes Financing
To accelerate development of molecular targeted systemic radiotherapy (SR, PRRT) based on its clinical stage technology Edinburgh, United Kingdom – Edinburgh Molecular Imaging Ltd (EMI), a
Epidarex Exeed Founded by Epidarex Capital to Advance Early Stage, Highly Innovative Life Science Assets
Epidarex’s therapeutic discovery engine will identify innovative early stage assets, providing hands-on scientific support and funding to drive drug discovery projects Exeed will mould and
LUNAC Therapeutics Led Project Awarded £3.14 million Under Innovate UK Biomedical Catalyst Programme, to Develop Next-Generation Anticoagulant
18 month project in collaboration with University of Leeds and Medicines Discovery Catapult will deliver a new compound for treatment of thrombosis Currently available anticoagulants
LUNAC Therapeutics Spun Out to Develop Next Generation Anticoagulants, and Announces Series A Funding Round
Novel anticoagulants to minimise bleeding risk by targeting activated Factor XII Builds on a decade of academic research into Factor XII Investment round led by
Enterprise Therapeutics awarded up to £5.7M ($7M) from Cystic Fibrosis Foundation to Support Clinical Development of Novel Chloride Channel Modulator
Support for clinical development up to end of Phase 2 for ETD002, first-in-class TMEM16A potentiator for the treatment of all cystic fibrosis patients Milestone Funding
Phase 2 Study Published in Ophthalmology Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to Age-Related Macular Degeneration
CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through
Epidarex Venture Partner Terri Burke will be a featured speaker at Cooley x JLABS @ TMC : Medtech Startup Fundamentals
Please click here to view the event’s agenda.